Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−12.75EUR
−189.73 MEUR
238.28 MEUR
7.72 M
About MORPHOSYS
Sector
Industry
CEO
Jean-Paul Kress
Website
Headquarters
Planegg
Employees (FY)
564
Founded
1992
ISIN
DE0006632003
FIGI
BBG000PTXM49
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange MORPHOSYS AG stocks are traded under the ticker MORD.
We've gathered analysts' opinions on MORPHOSYS AG future price: according to them, MORD price has a max estimate of 68.35 EUR and a min estimate of 68.00 EUR. Watch MORD chart and read a more detailed MORPHOSYS AG stock forecast: see what analysts think of MORPHOSYS AG and suggest that you do with its stocks.
MORD reached its all-time high on Jan 13, 2020 with the price of 145.90 EUR, and its all-time low was 12.05 EUR and was reached on Dec 16, 2022. View more price dynamics on MORD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track MORPHOSYS AG financials in yearly and quarterly reports right on TradingView.
MORPHOSYS AG is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
MORD earnings for the last quarter are −8.27 EUR per share, whereas the estimation was −1.13 EUR resulting in a −632.58% surprise. The estimated earnings for the next quarter are −2.02 EUR per share. See more details about MORPHOSYS AG earnings.
MORPHOSYS AG revenue for the last quarter amounts to 27.50 M EUR despite the estimated figure of 54.41 M EUR. In the next quarter revenue is expected to reach 49.07 M EUR.
MORD net income for the last quarter is −314.96 M EUR, while the quarter before that showed 48.27 M EUR of net income which accounts for −752.56% change. Track more MORPHOSYS AG financial stats to get the full picture.
No, MORD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 1, 2024, the company has 564.00 employees. See our rating of the largest employees — is MORPHOSYS AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MORPHOSYS AG EBITDA is −436.96 M EUR, and current EBITDA margin is −95.29%. See more stats in MORPHOSYS AG financial statements.
Like other stocks, MORD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MORPHOSYS AG stock right from TradingView charts — choose your broker and connect to your account.